MIAMI (AP) — Johnson & Johnson is facing allegations that it ignored evidence linking its baby powder to ovarian cancer and continued to promote its safety. The pharmaceutical giant chose to “deny, deny, deny” the potential risks associated with its iconic product, according to an attorney representing the widower of a woman who died from ovarian cancer after using the powder.
The case, which is scheduled to go to trial next week in Miami, Florida, raises significant questions about the ethical conduct of Johnson & Johnson and its marketing practices. The widower’s attorney argues that the company prioritized profits over consumer safety, knowingly disregarding scientific research and failing to issue proper warnings.
Johnson & Johnson has faced multiple lawsuits regarding the safety of its baby powder over the years. Thousands of women have come forward alleging that prolonged use of the talc-based product led to their diagnosis of ovarian cancer. The company has consistently maintained that its baby powder is safe and poses no health risks.
However, documents revealed in previous trials indicated that Johnson & Johnson was aware of the potential link between talcum powder and ovarian cancer as early as the 1970s. Internal memos and emails showed that executives discussed strategies to counter scientific studies suggesting a connection. The company has also been accused of targeting minority and low-income women in its marketing campaigns, exacerbating health disparities.
The upcoming trial will shed light on whether Johnson & Johnson adequately warned consumers about the potential risks and whether the company can be held legally responsible for the woman’s death. Legal experts anticipate that the widower’s attorney will present evidence suggesting that Johnson & Johnson knew about the dangers of its baby powder but intentionally concealed the information from the public.
This case is part of a larger wave of litigation against Johnson & Johnson and its talcum powder products. The outcome of this trial could potentially set a precedent for future lawsuits and have significant implications for the pharmaceutical industry as a whole. As the trial approaches, it remains to be seen how Johnson & Johnson will defend its actions and whether the evidence presented will persuade the jury to hold the company accountable for its alleged misconduct.